Cell Signaling Technology Logo - Extra Large

PathScan® Bcr/Abl Activity Assay: Phospho-c-Abl, Phospho-Stat5 and Phospho-CrkL Multiplex Western Detection Cocktail #5300

Inquiry Info. # 5300

Please see our recommended alternatives.

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    The PathScan® Multiplex Western Detection Cocktail offers a unique method to assay the inhibition of multiple proteins on one membrane without stripping and reprobing. This method saves the user valuable time while increasing accuracy and minimizing reagent waste. The Bcr/Abl Activity Assay allows the user to simultaneously detect the inhibition of phosphorylation of c-Abl, Stat5 and CrkL proteins in response to STI-571. The cocktail also includes Rab11 antibody to control protein loading.

    Protocol

    Specificity / Sensitivity

    Each phospho-antibody in this cocktail recognizes endogenous levels of only the phosphorylated form of its specific target. The Rab11 Antibody detects endogenous levels of its target protein independent of phosphorylation and is provided to control for protein loading.

    Species Reactivity:

    Human

    Source / Purification

    Antibodies are produced by immunizing animals with synthetic peptides. Polyclonal antibodies are purfied by protein A and peptide affinity chromatography.

    Background

    STI-571 (also known as Imatinib mesylate) is a tyrosine kinase (TK) inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor and c-Kit TKs (1-3). Results are encouraging in CML clinical trials, and STI-571 has become a paradigm for targeted cancer therapeutics (4-6). Signal transduction through phospho-tyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways (7-9). Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-cbl, Dok, SHC and CrkL (10-15). In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc and Stat5 are also activated in a Bcr-Abl kinase-dependent manner (16).
    1. Buchdunger, E. et al. (1996) Cancer Res 56, 100-4.
    2. Heinrich, M.C. et al. (2000) Blood 96, 925-32.
    3. Druker, B.J. et al. (1996) Nat Med 2, 561-6.
    4. Mauro, M.J. and Druker, B.J. (2001) Curr Oncol Rep 3, 223-7.
    5. Druker, B.J. et al. (2001) N Engl J Med 344, 1031-7.
    6. Druker, B.J. et al. (2001) N Engl J Med 344, 1038-42.
    7. Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65.
    8. Ullrich, A. and Schlessinger, J. (1990) Cell 61, 203-12.
    9. Cantley, L.C. et al. (1991) Cell 64, 281-302.
    10. ten Hoeve, J. et al. (1994) Blood 84, 1731-6.
    11. Matsuguchi, T. et al. (1994) J Biol Chem 269, 5016-21.
    12. Carpino, N. et al. (1997) Cell 88, 197-204.
    13. Sattler, M. et al. (1997) Oncogene 15, 2379-84.
    14. Di Cristofano, A. et al. (1998) J Biol Chem 273, 4827-30.
    15. Wisniewski, D. et al. (1999) Blood 93, 2707-20.
    16. Kabarowski, J.H. and Witte, O.N. (2000) Stem Cells 18, 399-408.

    Alternate Names

    Multiplex Western; stat5 a; stat5 b; stat5a; stat5b; Western cocktail

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.